Prelude Therapeutics (PRLD) Amortizatization of Intangibles (2021 - 2026)
Prelude Therapeutics (PRLD) posted Amortizatization of Intangibles of $388000.0 for Q1 2026, up 106.38% sequentially from $188000.0 in Q4 2025, and up 591.14% YoY from $56139.2 in Q1 2025.
Powered by 
Analysis
Prelude Therapeutics (PRLD) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Prelude Therapeutics has reported Amortizatization of Intangibles for 6 years, with the latest figure at $388000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 591.14% year-over-year to $388000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $838000.0 (down 72.24% YoY) and the FY2025 annual result came in at $371000.0, down 92.0% from the prior year.
- Amortizatization of Intangibles advanced to $388000.0 in Q1 2026 per PRLD's latest filing, from $188000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1.6 million in Q3 2023 and troughed at -$1.0 million in Q2 2022.
- A 5-year average of $369411.8 and a median of $359000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2025 and 2026: Amortizatization of Intangibles sank 105.13% in 2025, then surged 591.14% in 2026.
- Over 5 years, Amortizatization of Intangibles stood at $179000.0 in 2022, then soared by 498.32% to $1.1 million in 2023, then retreated by 11.2% to $951000.0 in 2024, then tumbled by 80.23% to $188000.0 in 2025, then jumped by 106.38% to $388000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $388000.0, $188000.0, and $49000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 678,000.00 |
| 10 | Prelude Therapeutics | 539.17 Mn | 258.54 Mn | - | 389,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 389,000.00 |
| Mar 31, 2026 | 388,000.00 |
| Dec 31, 2025 | 384,000.00 |
| Sep 30, 2025 | 383,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Mar 31, 2025 | 384,000.00 |
| Dec 31, 2024 | 951,000.00 |
| Sep 30, 2024 | 815,000.00 |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | 1.07 Mn |
| Sep 30, 2023 | 1.53 Mn |
| Jun 30, 2023 | 428,000.00 |
| Mar 31, 2023 | 446,000.00 |
| Dec 31, 2022 | 179,000.00 |
| Sep 30, 2022 | -986,000.00 |
| Jun 30, 2022 | -1.04 Mn |
| Mar 31, 2022 | -748,000.00 |
| Dec 31, 2021 | -2.29 Mn |
| Sep 30, 2021 | 356,000.00 |